Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032

• RLF-OD032 demonstrated bioequivalence to KUVAN^® Powder
• Study results support planned 505(b)(2) NDA submission in early 2026

GENEVA (OCT. 29, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced positive results from its pivotal bioequivalence clinical study evaluating RLF-OD032, Relief’s innovative and highly concentrated liquid formulation of sapropterin dihydrochloride, for the treatment of phenylketonuria (PKU).

The pivotal study achieved its primary pharmacokinetic endpoints, demonstrating that RLF-OD032 is bioequivalent to KUVAN^® Powder, the reference listed drug, as defined by the U.S. Food and Drug Administration. The randomized, open-label, two-way crossover study compared the pharmacokinetics of RLF-OD032 (administered without water) and the reference product (administered with water, as per its labeling) under fed conditions. RLF-OD032 was well tolerated, with no serious adverse events reported. These results are based on a pre-database lock analysis (soft lock) and are expected to be confirmed following final data verification.

“We are extremely pleased to have advanced RLF-OD032 from concept to clinical validation in just three years, demonstrating its bioequivalence and confirming its potential as the first ready-to-use liquid sapropterin formulation,” said Giorgio Reiner, chief scientific officer of Relief. “We believe this innovation will make a meaningful difference for individuals living with PKU, and we are now focused on completing the final regulatory steps to bring this product to market as quickly as possible.”

RLF-OD032 offers a novel approach to PKU management by addressing key limitations of current sapropterin therapies that must be mixed with large volumes of water. As a ready-to-use, highly concentrated liquid, RLF-OD032 can be administered directly, without water, offering a portable, low-volume, and patient-friendly alternative. Its up to 100-fold reduction in dose volume simplifies daily treatment and is expected to improve adherence, optimize outcomes, and enhance quality of life for children and adults living with PKU.

Relief plans to proceed with final data verification and completion of CMC activities in preparation for submission of a 505(b)(2) New Drug Application (NDA). The NDA is expected to be filed in early 2026, seeking U.S. marketing approval for the treatment of PKU, and will be subject to a 10-month FDA review under the 505(b)(2) pathway.

ABOUT RLF-OD032
RLF-OD032 is an innovative, ready-to-use, portable and highly concentrated formulation of sapropterin dihydrochloride in liquid suspension for oral administration, designed to lower blood phenylalanine levels in adult and pediatric PKU patients. It offers a more patient-friendly solution by significantly reducing the volume of medication required compared to current formulations. This advancement aims to enhance compliance, particularly among pediatric patients, who often struggle with the high volumes associated with existing sapropterin treatments. If approved, RLF-OD032 would be the first and only portable, ready-to-use liquid formulation of sapropterin dihydrochloride, with pending patent protection extending through at least 2043.

ABOUT PHENYLKETONURIA
Phenylketonuria (PKU) is a genetic disorder caused by a deficiency of the enzyme needed to break down phenylalanine (Phe), leading to a toxic buildup of Phe from the consumption of foods containing protein or aspartame. Individuals with PKU lack the ability to metabolize Phe, which is present in many foods. Without treatment, PKU can cause severe neurological and developmental issues. The standard treatment involves a lifelong phenylalanine-restricted diet supplemented with amino acid-based, phenylalanine-free medical foods to prevent protein deficiency and optimize metabolic control. However, this diet is highly restrictive and often creates barriers to social interaction, limiting compliance and increasing the risk of poor disease management.

ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief’s clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com.

CONTACT:
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com

DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as “believe,” “assume,” “expect,” “intend,” “may,” “could,” “will,” or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. The clinical results described herein are based on a pre-database lock analysis and remain subject to confirmation upon completion of final data verification and database lock. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

KUVAN^® is a registered trademark of BioMarin Pharmaceutical Inc., which is not connected to Relief, and no association or endorsement is implied.

FUTRUE increases adequate cash compensation under the squeeze-out

Gräfelfing, October 28, 2025 – Under agenda item 1 of the extraordinary general meeting of PharmaSGP Holding SE convened for October 31, 2025, the Management Board and Supervisory Board propose, at the request of FUTRUE GmbH, to transfer the shares of the remaining shareholders (minority shareholders) of PharmaSGP Holding SE to FUTRUE GmbH as the main shareholder in return for an adequate cash compensation in accordance with Sections 327a et seq. of the German Stock Corporation Act (AktG) (so-called squeeze-out).

The adequate cash compensation was originally set by FUTRUE GmbH at EUR 29.33 per PharmaSGP share. In view of the developments of the capital market and the business performance of PharmaSGP Holding SE in the meantime, ValueTrust, as a neutral expert, has updated its expert opinion. In light of this, FUTRUE GmbH has decided to increase the adequate cash compensation from EUR 29.33 to EUR 30.64 per share and has notified the Management Board of PharmaSGP Holding SE of this increase today.

Due to these developments, the Management Board and Supervisory Board have today amended their resolution proposal on agenda item 1 of the extraordinary general meeting on October 31, 2025, so that it now provides for an adequate cash compensation of EUR 30.64 per share.

The amended resolution proposal and other related documents, in particular, a supplement to the transfer report of FUTRUE GmbH explaining and justifying the adequacy of the adjusted cash compensation, as well as updated statements by the neutral expert and the court-appointed expert auditor, are available on the PharmaSGP Holding SE website under the heading “General Meeting.”

Further, an updated proxy form for instructing the company’s proxies, which refers to the amended proposal, is available on the PharmaSGP Holding SE website under the heading “General Meeting.”

CONTACT

cometis AG
Jakob Hafer
Phone: +49-611-20585522
Email: ir@pharmasgp.com

ABOUT PHARMASGP HOLDING SE

PharmaSGP is a leading consumer health company with a diversified portfolio of over-the-counter (OTC) pharmaceuticals and other healthcare products that are marketed with a focus on the pharmacy distribution channel. These products are mostly based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.

The Company’s core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RubaXX^® for rheumatic pain and Restaxil^® for neuralgic pain. Furthermore, PharmaSGP also offers leading products against sexual weakness and vertigo symptoms. Since introducing the first product from the current product portfolio in 2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy, Belgium, Spain and France. In September 2021, the product portfolio was expanded by the brands Baldriparan^®, Formigran^®, Spalt^® and Kamol^®, thus also strengthening or developing the indications pain and sleep disorder. The sales territory was expanded to include Switzerland and Eastern Europe. In 2024, PharmaSGP generated revenues of €118.8 million at an adjusted EBITDA margin of 31.3%.

Gerresheimer AG: Uwe Röhrhoff takes over as interim CEO for Dietmar Siemssen 

Duesseldorf, October 28, 2025. The Supervisory Board of Gerresheimer AG (ISIN: DE000A0LD6E6, “Gerresheimer”) has appointed Uwe Röhrhoff as the interim CEO of the Management Board, effective November 1, 2025. He succeeds Dietmar Siemssen, who will step down as CEO of Gerresheimer AG by mutual agreement with the Supervisory Board on October 31, 2025.

Uwe Röhrhoff previously held various management positions at Gerresheimer from 1991 to 2017, most recently serving as CEO from 2010 to 2017.

_______________________

End of inside information

Contact Gerresheimer AG

Investor Relations

Guido Pickert
Vice President Investor Relations

T +49 152 900 14145
gerresheimer.ir@gerresheimer.com

Media

Jutta Lorberg
Head of Corporate Communication
T +49 211 6181 264

jutta.lorberg@gerresheimer.com

Gerresheimer: Uwe Röhrhoff takes over as interim CEO for Dietmar Siemssen 

• Industry expert with many years of experience in the sector, including around 26 years in management positions at Gerresheimer
• Dietmar Siemssen to step down as CEO by mutual agreement with the Supervisory Board
• New formation of the Management Board

Duesseldorf, October 28, 2025. The Supervisory Board of Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industries has appointed Uwe Röhrhoff as interim CEO of the company’s Management Board, effective November 1, 2025. He succeeds Dietmar Siemssen, who, by mutual agreement with the Supervisory Board, will step down as CEO of Gerresheimer AG on October 31, 2025. Uwe Röhrhoff is familiar with Gerresheimer from his previous 26 years with the company from 1991 to 2017. He was appointed to the Management Board in 2003 and served as CEO of Gerresheimer from 2010 to 2017. Most recently, he worked as a consultant and supervisory board member for various companies. The experienced industry expert holds supervisory board mandates at Klöckner & Co. SE and Röchling SE & Co. KG, among others. The appointment of Uwe Röhrhoff as interim CEO completes the new formation of Gerresheimer’s Management Board for the time being.

“We are delighted to have gained Uwe Röhrhoff, a proven industry expert, as interim CEO,” said Dr. Axel Herberg, Chairman of the Supervisory Board of Gerresheimer AG. “As former CEO of Gerresheimer, he is extremely knowledgeable about the company and has a very clear understanding of the business and its challenges.”

Dietmar Siemssen steps down as CEO after seven years

Röhrhoff succeeds Dietmar Siemssen, who, by mutual agreement with the Supervisory Board, will step down as CEO on October 31, after seven years in office. He is thus paving the way for a personnel change at the top of the MDAX company.

“We would like to thank Dietmar Siemssen for his commitment and contribution to the strategic development of Gerresheimer,” said Dr. Axel Herberg. “Under his leadership, the company has transformed itself from a volume supplier to a provider of high-value systems and solutions for the pharma and biotech industries.”

Newly formed Management Board

The appointment of Uwe Röhrhoff as interim CEO completes the personnel changes to Gerresheimer’s Management Board for the time being. In September 2025, Wolf Lehmann replaced Dr. Bernd Metzner as CFO. On November 1, 2025, Uwe Röhrhoff will succeed Dietmar Siemssen as CEO and Achim Schalk will succeed Dr. Lukas Burkhard as a member of the Management Board.

About Gerresheimer 
Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of drug containment solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, cartridges, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With over 40 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. Together with Bormioli Pharma, the Group generated revenues of around EUR 2.4bn in 2024 and currently employs around 13,600 people. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).    
www.gerresheimer.com 

Contact Gerresheimer AG

PL BioScience Announces new Board Member Ole Henrik Bang-Andreasen

Aachen, Germany, 28 October 2025 – PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion and manufacturing, today announced the appointment of Ole Henrik Bang-Andreasen to its board of directors, following the passing of board member Reinhard Vogt.

Ole brings significant transatlantic industry experience, leadership expertise, and capital markets acumen to the board, and will be of great value as PL BioScience moves into a new era of accelerated development and expansion, and enhanced value creation. He currently serves as a Principal in the London office of AVANT BIO, a U.S.-based early-stage and growth equity firm, where he focuses on advancing healthcare and biotechnology ventures. Ole earned his Bachelor of Science in Accounting and Finance at Northeastern University in Boston, and his Master of Science in Econometrics at Boston University. He currently serves on the boards of PathPresenter, Wasteless Bio and HC Andersen Capital, and is Chairman of the board at Portunus Solutions.

Hatim Hemeda, CEO of PL BioScience, commented: “Working with Ole during this board seat transition has been a great pleasure. His deep scientific insight, combined with sharp investment acumen have already been highly beneficial to our team. We are excited to work together further as PL BioScience continues to strengthen its position as a leader in Human Platelet Lysate technology. At the same time, we are deeply saddened by the loss of our colleague, friend and mentor Reinhard Vogt.”

Ole Henrik Bang-Andreasen added: “Joining the PL BioScience (PLB) board is bittersweet with the passing of my colleague and mentor Reinhard Vogt. Taking the baton from Reinhard, I am looking forward to helping PLB build the world’s leading HPL company, starting with a new facility in Aachen, and a busy but exciting roadmap ahead. “

In memory of Reinhard Vogt

It is with deep sadness that PL BioScience GmbH shares news of the passing of Reinhard Vogt on September 8, 2025. Reinhard was a dear friend, mentor, and member of our Board of Directors since 2024.

Widely respected as a visionary in the life science industry, Reinhard’s experience, kindness, and passion for life sciences inspired everyone around him. We are grateful for his guidance and the time we shared. Our thoughts are with his family and friends at this time.

About PL BioScience:

PL BioScience GmbH, a life science company located in Aachen, Germany, specializes in the production and development of Human Platelet Lysate (HPL). The company has pioneered proprietary technology to produce fully artificial HPL, allowing for a fully lab-made, scalable supply of HPL. PL BioScience currently offers a comprehensive portfolio of donor-derived, natural HPL products tailored for a range of applications – the ELAREM^TM platform. From academic and preclinical research to cell therapy and biopharmaceutical manufacturing, ELAREM™ ensures seamless translations of regenerative medicine breakthroughs – from the lab to patients in need. PL BioScience is the only company worldwide holding a patent for the gamma-irradiation of HPL, covering the manufacturing process for ELAREM™ Ultimate-FD PLUS.

For more information on PL BioScience and the ELAREM™ platform, visit: https://www.pl-bioscience.com/

Contact:
Dr. Hatim Hemeda, CEO
PL BioScience GmbH
+49(0)24195719-100
info@pl-bioscience.com

Media contact:
MC Services AG
Raimund Gabriel, Dr. Regina Lutz
+49 (0)89 210 228 0

U.S.: Catherine Featherston
+1-203-444-4393
E-Mail: plbioscience@mcservices.eu

• Q3 sales show sustained growth in the implant business
• LOQTEQ® portfolio gains traction in all markets

aap Implantate AG (“aap”) recorded strong sales growth of 15% in the third quarter compared to the same quarter last year (Q3/2024). This is all the more significant given that the third quarter is traditionally the weakest quarter of the year.

The aap LOQTEQ® plate portfolio in particular grew in all markets and is enjoying increasing popularity among users thanks to its unique technical advantages. Orders totaling around EUR 400,000 could not be delivered in Q3/2025 due to high demand for top-of-the-range products and temporary production and supply bottlenecks, but they form a solid starting point for Q4/2025.

Q3/2025 – Sales figures

9M/2025 – Sales figures

In terms of regions, the largest region, EMEA, recorded growth of +5% compared to the previous year. Germany continued to grow slightly in Q3, supported by good growth in Spain/Portugal (+~30% compared to the previous year) and stable sales from other core markets such as South Africa and the Middle East.

In the US, intensified market development measures began to show initial success: the American subsidiary increased sales by 18% in local currency, which corresponds to an increase of 11% in euros. In USD terms, the gap from the first half of 2025 was thus closed in the first nine months.

In the LATAM region, sales in Q3 increased by 21% compared to the previous year. The main driver was the fast-growing foot and ankle business with a new product line that was very well received by the market.

The APAC region achieved exceptionally strong revenue growth of >200% in the third quarter. This was driven both by new customers who successfully launched on the market after completing all preparatory work, and by existing business, which grew by a clear double-digit percentage of over 40% compared to the previous year. The region is showing growing, sustainable market penetration, opening up solid growth prospects for the coming years.

Based on the first nine months, the strong third quarter helped to catch up with the previous year’s result and exceed it by 2%. Cumulative sales reached EUR 9.48 million (9M/2024: EUR 9.26 million).

aap is off to a solid start in the fourth quarter with an order backlog from Q3 of around EUR 400,000. Further expansion and market penetration are expected to further strengthen the sales base in the coming months.  aap is sticking to its forecast for 2025.

——————————————————————————————————————————————-

aap Implantate AG (ISIN DE0005066609) – General Standard/Regulated Market – All German stock exchanges –

About aap Implantate AG

aap Implantate AG is a global medical technology company based in Berlin, Germany. The company develops, manufactures, and markets products for traumatology. In addition to the innovative LOQTEQ® anatomical plate system, its IP-protected portfolio includes a wide range of screw plates. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects, such as antibacterial silver coating technology and magnesium-based implants. These technologies address critical problems in traumatology that have not yet been adequately solved. aap Implantate AG sells its products in Germany directly to hospitals, purchasing groups, and hospital networks, while internationally it primarily uses a broad network of distributors in around 25 countries. In the USA, the company relies on a sales strategy via distribution agents through its subsidiary aap Implants Inc. The shares of aap Implantate AG are listed in the General Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For further information, please visit our website at www.aap.de.

The figures presented in this press release may contain technical rounding differences that do not affect the overall statement.

Forward-looking statements

This release may contain forward-looking statements based on the current expectations, assumptions, and forecasts of the Management Board and the information currently available to it. Forward-looking statements are not guarantees of future developments and results. Various known and unknown risks, uncertainties, and other factors could cause the actual results, financial position, development, or performance of the company to differ materially from the estimates given here. These factors also include those described by aap in published reports. Forward-looking statements are therefore only valid on the date they are made. We assume no obligation to update the forward-looking statements made in this release or to adapt them to future events or developments.

If you have any questions, please contact: aap Implantate AG; Rubino Di Girolamo, Chairman of the Executive Board/CEO, Lorenzweg 5; 12099 Berlin

Tel.: +49 (0)30 75019 – 170; Fax: +49 (0)30 75019 – 290; Email: r.digirolamo@aap.de

Third BIOTECH SUMMIT AUSTRIA Gathers Industry Leaders in Graz

Graz, Austria – October 27, 2025. The third BIOTECH SUMMIT AUSTRIA brought together about 300 participants from 13 countries in Graz last week, highlighting Austria’s growing momentum in life sciences. Jointly organized by BIOTECH AUSTRIA, Human.technology Styria, and the Health Hub Tirol, the annual summit has become a key meeting point for biotech companies, investors and service providers to exchange insights, explore the latest trends, and strengthen connections across Austria’s biotech ecosystem and beyond.

Peter Llewellyn-Davies, President of BIOTECH AUSTRIA, is delighted: “The continued high turnout and very positive feedback underscore the summit’s role in reinforcing Austria’s position as a leading life sciences location and promoting cross-border collaboration. I would also like to sincerely thank all attendees, sponsors, and especially our co-hosts who helped make this event truly unforgettable.”

Keynotes set a practical, forward-looking tone: Harpreet Singh, CEO and Co-Founder of Immatics, recounted the company’s trajectory and emphasized that progress isn’t always a straight line, but requires resilience and flexibility. Caroline Schober (RCPE GmbH), speaking in line with BIOTECH AUSTRIA’s 2025 motto “Artificial vs. Agile Intelligence” explored the crucial role of the human factor for biotech innovation in an era increasingly shaped by AI. Patrick Frei, Founder & CEO of Venture Valuation, presented a deep dive into valuing biotech companies for financing and partnering and closed with a fireside chat going into a detailed analysis of his experience. The program also featured high-level panels on scientific challenges and opportunities or the latest trends in financing and venture capital, plus talks covering topics such as BIOTECH AUSTRIA’s Austrian life science strategy initiatives and its task forces, as well as company presentations and start-up pitches.

Lejla Pock, CEO of Human.technology Styria and local co-host of the summit, added: “Hosting this year’s Biotech Summit here in Graz again was a privilege. Innovation thrives where people meet, share ideas, and build trust, and that spirit of collaboration was visible throughout the event. Graz, with its scientific excellence and entrepreneurial spirit, provided the perfect backdrop for that exchange.”

Social and networking events supported deal-making and relationship building, from a pre-conference Hike & Dine through the Styrian vineyards to the dinner at the Schlossberg restaurant and dancing well into the morning hours. With several hundred meetings booked, the 1:1 partnering sessions allowed industry representatives from across the biotech value chain to build partnerships and explore new business opportunities.

Klaus Weinberger, CEO at Health Hub Tirol, concluded: “With such a strong participation and lively discussions, this year’s summit demonstrated the momentum and collaborative spirit of Austria’s biotech scene. We look forward to carrying this energy forward when the Summit returns to Innsbruck on October 13-14, 2026.”

For further information and to revisit highlights of the 3^rd BIOTECH SUMMIT AUSTRIA, please visit the BIOTECH SUMMIT AUSTRIA website.

For high-resolution images, please contact biotechaustria@mc-services.eu.

 For post-event inquiries and additional information, please contact:

BIOTECH AUSTRIA

Christine Llewellyn-Davies
Head of Operations
+43 670 6030601
Email: info@biotechaustria.org

Human.technology Styria

Lejla Pock
CEO

Eva Bucht
PR and Marketing
+43 699 188 99 708
Email: office@human.technology.at

Health Hub Tirol

Klaus Weinberger
CEO Health Hub Tirol

Petra Stöckl
Gesundheitsindustrie & Life Sciences
+43 676 843 101-248
Email: petra.stoeckl@healthhub.tirol

International Media and Investor Relations

MC Services AG
Dr. Cora Kaiser, Dr. Johanna Kobler
+49 89 210 228 0
Email: biotechaustria@mc-services.eu

About BIOTECH AUSTRIA

Since December 2020, BIOTECH AUSTRIA has been the voice of the Austrian biotech industry, enabling and connecting a non-governmental ecosystem so that businesses can start, grow and deliver world-changing innovation. Life Sciences are a key industry in Austria, and biotechnology is one of the fastest-developing sectors with high growth dynamics and international competitiveness. BIOTECH AUSTRIA is constantly expanding its network with new members and supporters in order to gather even more expertise under one roof. BIOTECH AUSTRIA represents over 100 biotech and life science companies, from start-ups to big pharma, academic institutions, research institutes, organisations and service providers to the sector. More information can be found at www.biotechaustria.org or on LinkedIn.

About Human.technology Styria

Human.technology Styria GmbH (HTS) is a cluster organization founded in 2004 with a focus on Life Sciences. It operates in three strategic priority areas: Medical Technology, Pharmaceuticals & Biotechnology, and Health & Sustainability. Additionally, HTS is actively involved in cross-cutting topics such as Start-Ups, Digitalization, and Qualification. The cluster sees itself as a bridge-builder between research, development, and industry, aiming to create synergies, enable innovations, forge new partnerships, and enhance the national and international visibility of the region. Companies within the cluster community benefit from exclusive service offerings related to Contact Management, Business Development, Internationalization, Networking, Events, Communication, and Knowledge Transfer. Within the environment of the Styrian Life Science Cluster, there are 150 companies with 40,000 employees generating a turnover of 5 billion euros. Approximately one-third of this can be attributed to the Pharma/Biotech sector. More information can be found at www.humantechnology.at.

About Health Hub Tirol

Tirol is a strong life sciences location. Successful companies and outstanding universities ensure a high research output, over 11,000 jobs and an industry turnover of almost 3 billion euros per year. Almost 100 innovative companies, institutions and universities are networked in the Cluster Life Sciences Tirol, which is based at the Standortagentur Tirol. In addition, the state of Tirol invests in a location development program for life sciences via Lebensraum Tirol Holding, which is implemented by Standortagentur Tirol and its subsidiaries. This program aims to drive innovation in the fields of medical technology, digital health, pharmaceuticals and biotechnology. Tirol is to be positioned as a top European life sciences region by 2030. One pillar of the program is the Health Hub Tirol, which works closely with the Cluster Life Sciences Tirol and Startup.Tirol to provide (lab) space and a wide range of startup services. More information can be found at www.standort-tirol.at and www.healthhub.tirol.

Hamburg, Germany, 27 October 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO) today announced that the Company has received a payment of US$ 25 m from Bristol Myers Squibb (NYSE: BMY) for scientific progress achieved within their strategic neuroscience partnership. The payment will advance further research and the partners’ joint pipeline of programs aimed at tackling neurogenerative diseases.

Launched in 2016, the collaboration focuses on discovering and developing disease-modifying treatments for neurodegenerative diseases, where current treatment options remain limited. Since then, the companies have built a strong pipeline of innovative programs, including EVT8683, in-licensed by Bristol Myers Squibb in 2021 as BMS-986419, that has completed Phase 1 clinical trials. The partnership was extended in 2023 for an additional eight years, reflecting the shared commitment to bringing transformative treatments into the clinic.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “Patients living with neurodegenerative conditions urgently need therapies that go beyond the management of symptoms. This achievement increases the depth of our collaboration with Bristol Myers Squibb. Together, we are translating emerging disease biology into potential therapeutic opportunities, with the goal of providing meaningful new options for patients suffering from neurodegenerative diseases.”

About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision.

Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.

With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility.

Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability.

With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.

Evotec’s global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For further information, please contact:

Media

Susanne Kreuter 
VP Head of Strategic Marketing 
Susanne.Kreuter@evotec.com 

Investor Relations

Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com